Abstract
Lovastatin inhibits 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA) reductase the rate limiting enzyme for synthesis of mevalonic acid, a precursor for cholesterol, farnesyl and geranylgeranyl pyrophosphate isoprenoids. Recent studies suggest it also has growth inhibitory properties. Posttranslational farnesyl or geranylgeranylation of low molecular weight GTP-binding proteins such as RAS and RHO are thought to be an essential step in activation of phosphorylation cascades such as the RAS–RAF-1–MEK-1–MAPK/ERK pathway which stimulate cell proliferation. In this study, we evaluated lovastatin effects on meningioma cell proliferation and activation of the MEK-1–MAPK/ERK pathway.
The effect of lovastatin on cell proliferation was assessed in eight human meningioma cell cultures stimulated by platelet derived growth factor (PDGF)-BB, cerebrospinal fluid (CSF), and fetal bovine serum (FBS). Concomitant lovastatin effects on phosphorylation/activation of mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/ERK) kinase (MEK-1) and MAPK/ERK were assessed by Western blot. Whether lovastatin acts via a mevalonate-dependent mechanism was also evaluated.
Coadministration of lovastatin completely blocked PDGF-BB, CSF, and FBS stimulation of [3H]-thymidine incorporation and cell proliferation. Lovastatin inhibited PDGF-BB's stimulatory effect in a dose dependent manner. Concomitant with its growth inhibitory effects, lovastatin reduced phosphorylation/activation of MEK-1/2 in five meningiomas and MAPK/ERK in seven. Coadministration of mevalonate with lovastatin partially restored PDGF's mitogenic effect.
Lovastatin is a potent inhibitor of meningioma cell proliferation which may act in part by reducing activation of MEK-1–MAPK/ERK pathway. Additional studies are warranted to assess whether lovastatin and similar HMG-CoA reductase inhibitors represent a new adjunctive chemotherapy for recurrent meningiomas.
Similar content being viewed by others
References
Quesney-Hueesens V, Wiley MH, Siperstein MD: Essential role of mevalovate in DNA synthesis. Proc Natl Acad Sci 76: 1556-1560, 1979
Habenicht AJR, Glomset JA, Ross R: Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle and Swiss 3t3 cells to divide after stimulation by platelet derived growth factor. J Biol Chem 255: 1534-1540, 1980
Volpe JJ, Obert KA: Relation of cholesterol to oligodendrocyte differentiation in C-6 glioma cells. J Neurochem 40: 530-537, 1983
Rowinsky EK, Windle JJ, Von Hoff DD: Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 17: 3631-3652, 1999
Gibbs JB, Pompliano DL, Mosser SD, Rands E, Lingham RB, Singh SB, Scolnick EM, Kohl NE, Oliff A: Selective inhibition of farnesyl-protein transferase blocks Ras processing in vivo. J Biol Chem 268: 7617-7620, 1993
Sumi S, Beauchamp D, Towwsend CM, Uchida T, Murakami M, Rajaraman S, Ishizuka J, Thompson JC: Inhibition of pancreatic adenocarcinoma cell growth with lovastatin. Gastroenterology 103: 982-989, 1992
Wejde J, Blegen H, Larsson H: Requirement for mevalonate in the control of proliferation of human breast cancer cells. Anti Cancer Res 12: 317-324, 1992
Crick DC, Andres DA, Danesi R, Macchia M, Waechter CJ: Geranylgeraniol overcomes the block of cell proliferation by Lovastatin in C6 glioma cells. J Neurochem 70: 2397-2405, 1998
Bouterfa HL, Sattelmeyer V, Czub S, Vordermark D, Roosen K, Tonn JC: Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. Anticancer Res 20: 2761-2771, 2000
Larner J, Jane J, Laws E, Packer R, Myers C, Shaffrey M: A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol 21: 579-583, 1998
Kikuchi K, Nagata Y, Abe Toshiaki: In vitro and in vivo antiproliferative effects of simvastatin, anHMG-CoAreductase inhibitor on human glioma cells. J Neuro-Oncol 34: 233-239, 1997
Beaupre DM, Kurzrock R: Ras and leukemia: from basic mechanisms to gene directed therapy. J Clin Oncol 17: 1071-1079, 1999
Fahraeus R, Fischer P, Kraus E, Lane DP: New approaches to cancer therapies. J Pathol 187: 138-146, 1999
Koper JW, Foekens JA, Braakman R, Lamberts SWJ: Effects of progesterone on the response to epidermal growth factor and other growth factors in cultured human meningioma cells. Cancer 46: 2545-2550, 1990
Johnson MD, Horiba M, Arteaga C: The epidermal growth factor receptor is associated with phospholipase C? in meningiomas. Human Pathol 25: 146-153, 1994
Weisman AS, Raguet SS, Kelly PA: Characterization of the epidermal growth factor receptor in human meningioma. Cancer Res 47: 2172-2176, 1987
Jones NR, Rossi ML, Gregoriou M, Hughes JT: Epidermal growth factor receptor expression in 72 meningiomas. Cancer 66: 152-155, 1990
Shamah SM, Alberta JA, Giannobile WV, Guha A, Kwon YK, Carroll RS, Black PM, Stiles CD: Detection of activated platelet-derived growth factor receptors in human meningioma. Cancer Res 57: 4141-4147, 1997
Todo T, Adams EF, Fahlbusch R, Dingermann T, Werner H: Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor. J Neurosurg 84: 852-859, 1996
Wang J-L, Nister M, Hermansson M, Westermark B, Ponten J: Expression of PDGF α-receptors in human meningioma cells. Int J Cancer 46: 772-778, 1990
Blenis J: Signal transduction via MAPK Proceed at your own RSK. Proc Natl Acad Sci 90: 5889-5892, 1994
Lewis TS, Shapiro PS, Ahn NG: Signal transduction through MAP Kinase cascades. Adv Cancer Res 74: 49-139, 1998
Johnson MD, Federspiel CF, Gold LI, Moses HL: Transforming growth factor-α and transforming growth factor-α receptor express ion in human meningioma cells. Am J Path 141: 631-642, 1992
Johnson MD, Woodard A, Kim P, Frexes-Steed M: Evidence for mitogen associated protein kinase activation and transduction of mitogenic signals from platelet derived growth factor in human meningioma cells. J Neurosurg 94: 293-300, 2001
Porter AG, Janicke RU: Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6: 99-104, 1999
Clerk A, Bogoyevitch MA, Andersson MB, Sudgen PH: Differential activation of protein kinase C isoforms by endothelin and phenylephrine and subsequent stimulation of p42 and p44 mitogen-activated protein kinases in ventricular myocytes cultured from neonatal rat hearts. Proc Natl Acad Sci 269: 32848-32857, 1994
Rubins JB, Greatens T, Kratzke RA, Tan AT, Polunovsky VA, Bitterman P: Lovastatin induces apoptosis in malignant mesothelioma cells. Am J Res Crit Care Med 157: 1616-1622, 1998
Mehta N, Hordines J, Sykes D, Doerr RJ, Cohen SA: Low density lipoproteins and lovastatin modulate organ-specific transendothelial migration of primary and metastatic human adenocarcinoma cell lines in vitro. J Clin Exp Metastasis 16: 587-594, 1998
Matar P, Rozados VR, Roggero EA, Scharovsky OG: Lovastatin inhibits tumor growth and metastasis development of a rat fibrosarcoma. Cancer Biother Radiopharm 13: 387-393, 1998
Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K: Lovastatin-mediated G1 arrest is through inhibition of the proteosome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci 96: 7797-7802, 1999
Conway A-M, Rakhit S, Pyne S, Pyne NJ: Platelet-derived growth-factor stimulation of the p42/p44 mitogen-activated protein kinase pathway in airway smooth muscle: role of pertussis-toxin sensitive G-proteins, c-Src tyrosine kinases and phosphoinositide 3-kinase. Biochem J 337: 171-177, 1999
Cross TG, Scheel-Toelner D, Henriquez NV, Deacon E, Salmon M, Lord J: Serine/threonine protein kinases and apoptosis. Exp Cell Res 256: 34-41, 2000
Holmstrom TH, Schmitz I, Soderstrom TS, Poukkula M, Johnson VL, Cho, Krammer PH, Eriksson JE:MAPK/ERK signaling in activated T cells inhibits CD95/FAs-mediated apoptosis downstream of DISC assembly. EMBO J 19: 5418-5428, 2000
Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME: Cell survival promoted by the Ras-MAPK signaling pathway transcription-dependent and independent mechanism. Science 286: 1358-1362, 1999
Jones KD, Couldwell WT, Hinton DR, Su Y, He S, Anker L, Law RE: Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. Biochem Biophys Res Commun 205: 681-687, 1994
Perez-Sala D, Mollinedo F: Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res Commun 199: 1209-1215, 1994
Agarwal B, Halmos B, Moss SF, Ramey WG, Holt PR: Lovastatin sensitizes colon cancer HT-29 cells to apoptosis induced by chemotherapeutic agents. Proc Am Assoc Cancer Res 39: 68, 1998
Macaulay RJ, Wang W, Dimitroulakos J, Becker LE, Yeger H: Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro. J Neuro-Oncol 42: 1-11, 1999
Prassana P, Thibault A, Liu L, Samid D: Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J Neurochem 66: 710-716, 1996
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Johnson, M.D., Woodard, A., Okediji, E.J. et al. Lovastatin is a Potent Inhibitor of Meningioma Cell Proliferation: Evidence for Inhibition of a Mitogen Associated Protein Kinase. J Neurooncol 56, 133–142 (2002). https://doi.org/10.1023/A:1014588214966
Issue Date:
DOI: https://doi.org/10.1023/A:1014588214966